The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
Abstract
PURPOSE: To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy. MATERIALS AND METHODS: Eighty-one cohorts of patients with stage III or IV ovarian carcinoma (6,885 patients) were identified from articles in MEDLINE (1989 through 1998). Linear regression models, with weighted correlation calculations, were used to assess the effects on log median survival time of the proportion of each cohort undergoing maximal cytoreduction, dose-intensity of the platinum compound administered, proportion of patients with stage IV disease, median age, and year of publication. RESULTS: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables (P < .001). Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival time. When actuarial survival was estimated, cohorts with ≤ 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts with more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months—an increase of 50%. The relationship between platinum dose-intensity and log median survival time was not statistically significant. CONCLUSION: During the platinum era, maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III or IV ovarian carcinoma. Consistent referral of patients with apparent advanced ovarian cancer to expert centers for primary surgery may be the best means currently available for improving overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Impact of Hospital Volume on Operative Mortality for Major Cancer Surgery
Begg, C. B. (1998) · JAMA · doi:10.1001/jama.280.20.1747 · Cited by 1,657
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Hillner, B. E., Smith, T. J., & Desch, C. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2327 · Cited by 638
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90100-w · Cited by 544
Eisenkop, S. M., Friedman, R. L., & Wang, H.-J. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.4955 · Cited by 507
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983) · PubMed · Cited by 437
Harmon, J. W., Tang, D. G., Gordon, T. A., Bowman, H. M., Choti, M. A., Kaufman, H. S., Bender, J. S., Duncan, M. D., Magnuson, T. H., Lillemoe, K. D., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00013 · Cited by 394
Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.520 · Cited by 381
Cited by
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Self-citationNeoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Self-citationNCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Self-citationCho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Chi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., Hensley, M., & Barakat, R. R. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.051 · Cited by 634
Chi, D. S., Eisenhauer, E. L., Zivanovic, O., Sonoda, Y., Abu-Rustum, N. R., Levine, D. A., Guile, M. W., Bristow, R. E., Aghajanian, C., & Barakat, R. R. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.018 · Cited by 591
Self-citationInvasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
Peres, L. C., Cushing-Haugen, K. L., Köbel, M., Harris, H. R., Berchuck, A., Rossing, M. A., Schildkraut, J. M., & Doherty, J. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy071 · Cited by 554
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 483
Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465
Kurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Culp, S. H., Schellhammer, P. F., & Williams, M. B. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.012 · Cited by 434
Chang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Self-citationImproved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Harter, P., Bois, A. D., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schröder, W., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9058-0 · Cited by 425
Fagotti, A., Ferrandina, G., Fanfani, F., Ercoli, A., Lorusso, D., Rossi, M., & Scambia, G. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.021 · Cited by 413
Eisenkop, S. M., Spirtos, N. M., Friedman, R. L., Lin, W.-C. M., Pisani, A. L., & Perticucci, S. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00278-6 · Cited by 410
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Optimal primary surgical treatment for advanced epithelial ovarian cancer
Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M., & Naik, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007565.pub2 · Cited by 403
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Bristow, R. E., Puri, I., & Chi, D. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.033 · Cited by 374
Self-citationRay-Coquard, I., Morice, P., Lorusso, D., Prat, J., Oaknin, A., Pautier, P., & Colombo, N. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy001 · Cited by 374
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., et al. (2006) · Cancer · doi:10.1002/cncr.21845 · Cited by 350
Buys, S. S., Partridge, E., Greene, M. H., Prorok, P. C., Reding, D., Riley, T. L., Hartge, P., Fagerstrom, R. M., Ragard, L. R., Chia, D., et al. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.005 · Cited by 346
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Diagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 322
Fagotti, A., Ferrandina, G., Fanfani, F., Garganese, G., Vizzielli, G., Carone, V., Salerno, M. G., & Scambia, G. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.06.052 · Cited by 315
Epithelial Ovarian Cancer: A Review of Current Management
Guppy, A. E., Nathan, P. D., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2005.05.009 · Cited by 311
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Self-citationPrimary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A.-T., & Vlastos, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4208 · Cited by 306
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma
Engelen, M. J. A., Kos, H. E., Willemse, P. H. B., Aalders, J. G., de Vries, E. G. E., Schaapveld, M., Otter, R., & van der Zee, A. G. J. (2006) · Cancer · doi:10.1002/cncr.21616 · Cited by 305
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Armstrong, D. K. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_5-20 · Cited by 303
Self-citationClinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Colombo, N., Peiretti, M., Garbi, A., Carinelli, S., Marini, C., & Sessa, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds223 · Cited by 290
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Enhanced Recovery in Gynecologic Surgery
Kalogera, E., Bakkum-Gamez, J. N., Jankowski, C. J., Trabuco, E., Lovely, J. K., Dhanorker, S., Grubbs, P. L., Weaver, A. L., Haas, L. R., Borah, B. J., et al. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31829aa780 · Cited by 285
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
Vernooij, F., Heintz, P., Witteveen, E., & van der Graaf, Y. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.02.030 · Cited by 280
Positive Surgical Margins in the 10 Most Common Solid Cancers
Orosco, R. K., Tapia, V. J., Califano, J. A., Clary, B., Cohen, E. E. W., Kane, C., Lippman, S. M., Messer, K., Molinolo, A., Murphy, J. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23403-5 · Cited by 279
Bakrin, N., Bereder, J. M., Decullier, E., Classe, J. M., Msika, S., Lorimier, G., Abboud, K., Meeus, P., Ferron, G., Quenet, F., et al. (2013) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2013.09.030 · Cited by 272
Hoogstins, C. E. S., Tummers, Q. R. J. G., Gaarenstroom, K. N., de Kroon, C. D., Trimbos, J. B. M. Z., Bosse, T., Smit, V. T. H. B. M., Vuyk, J., van de Velde, C. J. H., Cohen, A. F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2640 · Cited by 271
Heidenreich, A., Pfister, D., & Porres, D. (2015) · Journal of Urology · doi:10.1016/j.juro.2014.09.089 · Cited by 268
Boruta, D. M., Gehrig, P. A., Fader, A. N., & Olawaiye, A. B. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.06.011 · Cited by 254
Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E., & Ioannidis, J. P. A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj443 · Cited by 187
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., et al. (2019) · Cancers · doi:10.3390/cancers11050655 · Cited by 102
A seven-gene prognostic model for platinum-treated ovarian carcinomas
Sabatier, R., Finetti, P., Bonensea, J., Jacquemier, J., Adelaide, J., Lambaudie, E., Viens, P., Birnbaum, D., & Bertucci, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.219 · Cited by 38
Port site resection after laparoscopy in advance ovarian cancer surgery: time to abandon?
Lago, V., Gimenez, L., Matute, L., Padilla-Iserte, P., Cárdenas-Rebollo, J. M., Gurrea, M., Montero, B., Montoliu, G., & Domingo, S. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.01.007 · Cited by 18
Skaznik-Wikiel, M. E., Lesnock, J. L., McBee, W. C., Beriwal, S., Zorn, K. K., Richard, S. D., Krivak, T. C., & Edwards, R. P. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318234f833 · Cited by 15
Metadata
- Authors
- Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1248-1259
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2099521317
- Cited by
- 2,312
- References
- 27
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.